# Isabl GxT: A clinically actionable whole genome and transcriptome precision medicine platform

> **NIH NIH R44** · ISABL INC. · 2024 · $991,890

## Abstract

Project Summary
Isabl Inc. is a Memorial Sloan Kettering Cancer Center spin out, aiming to launch a cancer
whole genome and transcriptome sequencing (cWGTS) diagnostic test for pediatric and rare
cancer patients. The product of this SBIR is Isabl GxT, a precision medicine platform that
incorporates cWGTS data into a robust data science framework to enable clinically actionable
reporting in a clinically relevant timeframe and facilitate novel biomarker discovery in oncology.
Isabl has generated significant feasibility and clinical utility data and obtained breakthrough
device designation by the FDA. The aims of this project are: 1) perform analytical and clinical
validity studies, 2) develop a commercial grade clinical bioinformatics platform, and 3) extend
utility of the existing test to additional biospecimen types. The long-term objective is to empower
oncology with one comprehensive cancer test.

## Key facts

- **NIH application ID:** 10815789
- **Project number:** 5R44CA281474-02
- **Recipient organization:** ISABL INC.
- **Principal Investigator:** Juan Santiago Medina
- **Activity code:** R44 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $991,890
- **Award type:** 5
- **Project period:** 2023-04-01 → 2026-03-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10815789

## Citation

> US National Institutes of Health, RePORTER application 10815789, Isabl GxT: A clinically actionable whole genome and transcriptome precision medicine platform (5R44CA281474-02). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10815789. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*